Latest News
Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Atara Biotherapeutics To Participate at the Stifel Virtual Cell Therapy Forum
Atara Biotherapeutics’ Ebvallo™ (tabelecleucel) Wins Prix Galien International Award for Best Product for Orphan/Rare Diseases
Latest Financial Results
![](https://d1io3yog0oux5.cloudfront.net/_7fb581bcab6ebc24e8a72de53833052d/atarabio/db/805/6333/image.jpg)
Latest Annual Filing
For Fiscal Year Ending Dec 31, 2023
Report Links
Email Alerts
Sign up today and receive company updates straight to your inbox.
![](https://d1io3yog0oux5.cloudfront.net/_7fb581bcab6ebc24e8a72de53833052d/atarabio/db/805/6344/image.jpg)
Company Overview
Atara is harnessing the natural power of the immune system to develop off-the-shelf cell therapies for difficult-to-treat cancers and autoimmune conditions that can be rapidly delivered to patients from inventory. With cutting-edge science and differentiated approach, Atara is the first company in the world to receive regulatory approval of an allogeneic T-cell immunotherapy. Our advanced and versatile T-cell platform does not require T-cell receptor or HLA gene editing and forms the basis of a diverse portfolio of investigational therapies that target EBV, the root cause of certain diseases, in addition to next-generation AlloCAR-Ts designed for best-in-class opportunities across a broad range of hematological malignancies and B-cell driven autoimmune diseases. Atara is headquartered in Southern California.
Investor & Media Contacts
Investor and Media Relations
Jason Awe, Ph.D.
Senior Director, Corporate Communications & Investor Relations
T: (805) 217-2287
jawe@atarabio.com
Transfer Agent
Computershare Trust Company, N.A.
P.O. Box 505000
Louisville, KY 40233
T: (781) 575-2879
web.queries@computershare.com